I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Inflammatory Bowel Disease

What's new

Sign up or login to unlock the full suite of MEDICALLY features

Feb 25 / Roche
New frontiers in inflammatory bowel disease TL1A inhibition – from mode of action to clinical application
This symposium discussed how the current unmet medical need in IBD needs and how anti-TL1A therapies have the potential to address that need highlighting data from recent trials and a overview of the proposed mechanism of action of TL1A.

Sign up or login to unlock the full suite of MEDICALLY features

Feb 22 / Roche and Genentech
Treatment with RO7790121 induces and maintains histologic and histologic-endoscopic improvement and remission in moderately to severely active Ulcerative Colitis - Results from TUSCANY-2
Histologic and endoscopic improvement and remission data from the TUSCANY-2 trial. This was a randomised, double-blind, placebo-controlled, dose-ranging Phase IIb study of RO7790121, an antibody against tumour necrosis factor like ligand 1A (anti-TL1A) in adults with moderately to severely active ulcerative colitis.

Sign up or login to unlock the full suite of MEDICALLY features

Feb 21 / Roche and Genentech
RO7790121 shows early and rapid symptomatic remission in the treatment of moderately to severely active Ulcerative Colitis - Findings from the phase 2b TUSCANY-2 trial
Data from post-hoc analyses of patient-reported outcomes (PROs) from the TUSCANY-2 trial. This was a randomised, double-blind, placebo-controlled, dose-ranging Phase IIb study of RO7790121, an antibody against tumour necrosis factor like ligand 1A (anti-TL1A) in adults with moderately to severely active ulcerative colitis.
Upcoming congresses
Access to Roche and Genentech’s latest medical information
View related congresses

Ask a question or share feedback